Enzomenib Receives FDA Breakthrough Therapy Designation
Sumitomo Pharma America says the FDA granted breakthrough therapy designation to enzomenib (DSP-5336) for treatment of R/R KMT2A-rearranged acute leukemia.
Sumitomo Pharma America says the FDA granted breakthrough therapy designation to enzomenib (DSP-5336) for treatment of R/R KMT2A-rearranged acute leukemia.